<strong>Glial Cells Protect Neurons against Oxidative Stress in Huntington’s Disease</strong>

Abstract

Abstract:Oxidative stress refers to elevated intracellular levels of reactive oxygen species (ROS) which cause damage to lipids, proteins and DNA. Changes in these macromolecules are involved in myriad pathological changes and progression of diseases, especially neurodegenerative diseases (NDD). NDD are usually featured by progressive neuron loss, accompanied with inclusions in neurons or glial cells. In NDD, glial cells may play a vital role in the functioning of neurons and cellular survival through an antioxidant way. Conversely, neurons could modulate the activities of glia in different ways. In this review, the main purposes were to summarize the characteristics and functions of glial cells in Huntington’s disease (HD). The connection between oxidative stress and HD, and state the cross talk between these interactive elements were also discussed.

Key words:glial cells,neurons,oxidative stress,Huntington&,rsquo,s disease

CLC Number:

R964

GAO Yan, CHU Shi-feng, CHEN Nai-hong.Glial Cells Protect Neurons against Oxidative Stress in Huntington’s Disease[J]. Acta Neuropharmacologica, 2014, 4(3): 22-30.

References

[1] Manfred Saran, Wolf Bors. Signalling by O2− and NO: how far can either radical, or any specific reaction product, transmit a message under in vivo conditions? [J]. Chem Biol Interacti, 1994, 90(1): 35-45.

[2] Manfred Saran. To what end does nature produce superoxide? NADPH oxidase as an autocrine modifier of membrane phospholipids generating paracrine lipid messengers [J]. Free Radic Res, 2003, 37(10): 1045-1059.

[3] K A Sieradzan, D M A Mann, The selective vulnerability of nerve cells in Huntington's disease [J]. Neuropathol Appl Neurobiol, 2001, 27: 1-21.

[4] Li Xiao-jiang, Li Shi-hua Large animal models of huntington's disease [J]. Curr Top Behav Neurosci, 2013, 2(1): 3-19.

[5] Mahmoud A Pouladi, A Jennifer Morton, Michael R Hayden. Choosing an animal model for the study of Huntington's disease[J]. Nat Rev Neurosci, 2013, 14(10): 708-721.

[6] Susan E Browne, M Flint Beal. Oxidative damage in Huntington's disease pathogenesis [J]. Antioxid Redox Signal, 2006, 8(11-12): 2061-2073.

[7] Yeun Su Choo, Mao Zheng-kuan, Gavil VW Johnson, et al. Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model[J]. Neurosci Lett, 2005, 386(1): 63-68.

[8] Marie Therese Besson, Pascale Dupont, Yih-Woei C Fridell et al. Increased energy metabolism rescues glia-induced pathology in a Drosophila model of Huntington's disease [J]. Human Molecular Genetics, 2010, 19(17): 3372-3382.

[9] Werner J H Koopman, Leo G J Nijtmans, Cindy E J Dieteren, et al. Mammalian mitochondrial complex I: biogenesis, regulation, and reactive oxygen species generation [J]. Antioxid Redox Signal, 2010, 12: 1431-1460.

[10] Simone Fulda, Adrienne M Gorman, Osamu Hori, et al. Cellular stress responses: cell survival and cell death [J]. Int J Cell Biol, 2010, 2010: 214074.

[11] David C Chan. Mitochondria: dynamic organelles in disease, aging, and development [J]. Cell, 2006, 125(7): 1241-1252.

[12] Abhishek Chandra, Ashu Johri, M Flint Beal. Prospects for neuroprotective therapies in prodromal Huntington's disease [J]. Mov Disord, 2014, 29(3): 285-293.

[13] George E Barreto, Janneth Gonzalez, Yolima Torres, et al. Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury [J]. Neurosci Res, 2011, 71(2): 107-113.

[14] Joana M Gil, Ana Cristina Rego. Mechanisms of neurodegeneration in Huntington's disease [J]. Eur J Neurosci, 2008, 27(11): 2803-2820.

[15] Chen Xue-ping, Guo Chun-yan, J Kong. Oxidative stress in neurodegenerative diseases [J]. Neural Regener Res, 2012, 7(5): 376-385.

[16] M Alba Sorolla, Gemma Reverter-Branchat, Jordi Tamarit, et al. Proteomic and oxidative stress analysis in human brain samples of Huntington disease [J]. Free Radic Biol Med, 2008, 45(5): 667-678.

[17] Alexandra Benchoua, Yael Trioulier, Diana Zala, et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin [J]. Mol Biol Cell, 2006, 17(4): 1652-1663.

[18] Tabrizi S J, Cleeter M W, Xuereb J, et al. Biochemical abnormalities and excitotoxicity in Huntington's disease brain [J]. Ann Neurol, 1999, 45(1): 25-32.

[19] Browne S E, Bowling A C, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia [J]. Ann Neurol, 1997, 41(5): 646-653.

[20] Trushina E, McMurray C T. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases [J]. Neuroscience, 2007, 145(4): 1233-1248.

[21] Mikhail B Bogdanov, Robert J Ferrante, Stefan Kuemmerle, et al. Increased vulnerability to 3-nitropropionic acid in an animal model of huntington's disease [J]. J Neurochem, 1998, 71(6): 2642-2644.

[22] Peter Klivenyi, Robert J Ferrante, Gabrielle Gardian, et al. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease [J]. J Neurochemistry, 2003, 87(1): 272.

[23] Robert J Ferrante, Ole A Andreassen, Alpaslan Dedeoglu, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of huntington’s disease [J]. J Neuroscience, 2002, 22(5): 1592–1599.

[24] Wang-Tso Lee, Chang Chen. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease [J]. Prog Neurobiol, 2004, 72(2): 87-110.

[25] DPhil Elsdon Storey, Neil W Kowall, Stephen F Finn, et al. The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex [J]. Ann Neurol, 1992, 32(4): 526-534.

[26] Shilpa Ramaswamy, Jodi L McBride, Jeffrey H Kordower. Animal models of huntington’s disease [J]. ILAR Journal, 2007, 48(4): 356-373.

[27] Gyung W Kim, Pak H Chan. Oxidative stress and neuronal DNA fragmentation mediate age-dependent vulnerability to the mitochondrial toxin, 3-nitropropionic acid, in the mouse striatum [J]. Neurobiol Dis, 2001, 8(1): 114-126.

[28] Emmanuel Brouillet, Francoise Conde, M F Beal, et al. Replicating huntington's disease phenotype in experimental animals [J]. Prog Neurobiol, 1999, 59(5): 427-468.

[29] Michael A La Fontaine, James W Geddes, Andrea Banks, et al. Effect of exogenous and endogenous antioxidants on 3-nitropropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease [J]. J Neurochem, 2000, 75(4): 1709-1715.

[30] Gyung W Kim, Jean-Christophe Copin, Makoto Kawase, et al. Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3- nitropropionic acid [J]. J Cereb Blood Flow Metab, 2000, 20(1): 119-129.

[31] Schulz J B, Matthews R T, Henshaw M F, et al. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases [J]. Neuroscience, 1996, 71(4): 1043-1048.

[32] McCracken E, Dewar D, Hunter A J. White matter damage following systemic injection of the mitochondrial inhibitor 3-nitropropionic acid in rat [J]. Brain Research, 2001, 892(2): 329-335.

[33] Isaac Tunez, Inmaculada Tasset, Veronica Perez-De La Cruz, et al. 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future [J]. Molecules, 2010, 15(2): 878-916.

[34] Theodore A Alston, Leena Mela, Harold J Bright. 3-Nitropropionate, the toxic substance of Indigofera, is a suicideinactivator of succinate dehydrogenase [J]. Proc Natl Acad Sci, 1977, 74(9): 3767-3771.

[35] Liu W, Tang Y, Feng J. Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system [J]. Life Sci, 2011, 89(5-6): 141-146.

[36] Hakan Aldskogius, Elena N Kozlova. Central neuron-gial and glial-glial interactions following axon injury [J]. Prog Neurobiol, 1998, 55(1): 1-26.

[37] Tong Xiao-ping, Ao Yan, Guido C Faas, et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice [J]. Nat Neurosci, 2014, 17(5): 694-703.

[38] Anna Maria Colangelo, Giovanni Cirillo, Maria Luisa Lavitrano, et al. Targeting reactive astrogliosis by novel biotechnological strategies [J]. Biotechnol Adv, 2012, 30(1): 261-271.

[39] Sarika Singh, Supriya Swarnkar, Poonam Goswami, et al. Astrocytes and microglia: responses to neuropathological conditions [J]. Int J Neurosci, 2011, 121(11): 589-597.

[40] Marcus Calkins, Marcelo R Vargas, Delinda A Johnson, et al. Astrocyte-speci?c overexpression of Nrf2 protects striatal neurons from mitochondrial complex II inhibition [J]. Toxicol Sci, 2010, 115(2): 557-568.

[41] Anna Maria Colangelo, Lilia Alberghina, Michele Papa. Astrogliosis as a therapeutic target for neurodegenerative diseases [J]. Neurosci Lett, 2014, 565:56-64.

[42] Wolfgang J Streit, Robert E Mrak, W Sue Griffin. Microglia and neuroinflammation: a pathological perspective [J]. J Neuroinflammation, 2004, 1(1): 14.

[43] Ridet J L, A Privat S K, Malhotra F H Gage, et al. Reactive astrocytes: cellular and molecular cues to biological function [J]. Trends Neurosci, 1997, 20(12): 570-577.

[44] Shilpee Singh, Magdalena Misiak, Cordian Beyer, et al. Cytochrome c oxidase isoform IV-2 is involved in 3-nitropropionic acid-induced toxicity in striatal astrocytes [J]. Glia, 2009, 57(14): 1480-1491.

[45] Nicholas J Maragakis, Jeffrey D Rothstein, Mechanisms of disease: astrocytes in neurodegenerative disease [J]. Nat Clin Pract Neurol, 2006, 2(12): 679-689.

[46] Markus Kipp, Serkan Karakaya, Justuna Pawlak, et al. Estrogen and the development and protection of nigrostriatal dopaminergic neurons: concerted action of a multitude of signals, protective molecules, and growth factors [J]. Front Neuroendocrinol, 2006, 27(4): 376-390.

[47] Dugan L L, Bruno V M G, Amagasu S M, et al. Glia modulate the response of murine cortical neurons to excitotoxicity: glia exacerbate AMPA neurotoxicity [J]. J Neuroscience, 1995, 15(6): 4545-4555.

[48] George Barreto, Janneth Gonzalez, Francisico Capani, et al. Neuroprotective agents in brain injury: a partial failure? [J]. Int J Neurosci, 2012, 122(5): 223-226.

[49] Anna Sofia Falcao, Rui F M Sliva, Ana Rita Vaz, et al. Cross-talk between neurons and astrocytes in response to bilirubin: early beneficial effects [J]. Neurochem Res, 2013, 38(3): 644-659.

[50] Fernandez-Fernandez S, Almeida A, Bolanos J P. Antioxidant and bioenergetic coupling between neurons and astrocytes [J]. Biochem J, 2012, 443(1): 3-11.

[51] Juan P Bolaños, Angeles Almeida, Victoria Stewart, et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases [J]. J Neurochemistry, 1997, 68(6): 2227-2240.

[52] Igor Allaman, Mireille Belanger, Pierre J Magistretti. Astrocyte-neuron metabolic relationships: for better and for worse [J]. Trends Neurosci, 2011, 34(2): 76-87.

[53] Andy Y Shih, Heidi Erb, Sun Xiao-jian, et al. Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation [J]. J Neurosci, 2006, 26(41): 10514-10523.

[54] Marcelo R Vargas, Jeffrey A Johnson. The Nrf2–ARE cytoprotective pathway in astrocytes [J]. Expert Rev Mol Med, 2009, 11: e17.

[55] Pei-Chun Chen, Marcelo R Vargas, Amar K Pani, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte [J]. Proc Natl Acad Sci USA, 2009, 106(8): 2933-2938.

[56] Marzai Perluigi, H Fai Poon, William Maragos, et al. Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice [J]. Molecular Cellular Proteomics, 2005, 4(12): 1849-1861.

[57] Fu Ru-ying, Shen Qing-yu, Xu Peng-fei, et al. Phagocytosis of microglia in the central nervous system diseases [J].Mol Neurobiol, 2014, 49(3):1422-1434.

[58] Denis Soulet, Serge Rivest. Microglia [J]. Curr Biol, 2008, 18(12): R506-R508.

[59] Guido Stollg, Sebastian Jander. The role of microglia and macrophages in the pathophysiology of the CNS [J]. Prog Neurobiol, 1999, 58(3): 233-247.

[60] Jochen Gehrmann, Yoh Matsumoto, Georg W Kreutzberg. Microgla: intrinsic immuneffector cell of the brain [J]. Brain Res Rev, 1995, 20(3): 269-287.

[61] Seung U Kim, Jean de Vellis. Microglia in health and disease [J]. J Neurosci Res, 2005, 81(3): 302-313.

[62] Guo-Fang Tseng, Yueh-Jan Wang, Quin-Chen Lai. Perineuronal microglial reactivity following proximal and distal axotomy of rat rubrospinal neurons [J]. Brain Research, 1996, 715(1-2): 32-43.

[63] Georg W Kreutzberg. Microglia: a sensor for pathological events in the CNS [J]. GLIA, 1996, 19(8): 312-318.

[64] Elisabetta Polazzi, Tatiana Gianni, Antonio Contestabile. Microglial cells protect cerebellar granule neurons from apoptosis: evidence for reciprocal signaling [J]. Glia, 2001, 36(3): 271-280.

[65] Stella Elkabes, Emanuel M DiCicco-Bloom, Ira B Black. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function [J]. J Neuroscience, 1996, 16(8): 2508-2521.

[66] Phoebe Harjes, Erich E Wanker. The hunt for huntingtin function: interaction partners tell many different stories [J]. Trends Biochem Sci, 2003, 28(8): 425-433.

[67] Mel B Feany, Albert R La Spada. Polyglutamines stop traffic: axonal transport as a common target in neurodegenerative diseases [J]. Neuron, 2003, 40(1-9): 1-2.

[68] Yu Zhao-xue, Li Shi-hua, Joy Evans, et al. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease [J]. J Neurosci, 2003, 23(6): 2193-2202.

[69] P Hemachandra Reddy, Maya Williams, Vinod Charles, et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA [J]. Nature Genetics, 1998, 20(2): 198-202.

[70] Juan Perucho, Maria Jose Casarejos, Ana Gomez, et al. Striatal infusion of glial conditioned medium diminishes huntingtin pathology in r6/1 mice [J]. PLoS One, 2013, 8(9): e73120.

[71] Jennifer Bradford, Ji-Yeon Shin, Meredith Roberts, et al. Mutant huntingtin in glial cells exacerbates neurological symptoms of huntington disease mice [J]. J Biological Chemistry, 2010, 285(14): 10653-10661.

[72] Ji-Yeon Shin, Fang Zhi-hui, Yu Zhao-xue et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity [J]. JCB, 2005, 171(6): 1001-1012.

[73] Suzanne Tydlacka, Chuan-En Wang, Wang Xue-jun, et al. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons [J]. J Neurosci, 2008, 28(49): 13285-13295.

[74] James A Dowell, Jeffrey A Johnson. Mechanisms of Nrf2 protection in astrocytes as identified by quantitative proteomics and siRNA screening [J]. PLoS ONE, 2013, 8(7): e70163.

[75] Emmanuel Brouillet, Carine Jacquard, Nicolas Bizat, et al. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease [J]. J Neurochem, 2005, 95(6): 1521-1540.

[76] J C Lievens, B Woodman, A Mahal, et al. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice [J]. Neurobiol Dis, 2001, 8(5): 807-821.

[77] Thomas W Kensler, Nobunao Wakabayashi, Shyam Biswal. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway [J]. Annu Rev Pharmacol Toxicol, 2007, 47: 89-116.

[78] Ma Qiang, Lori Battelli, Ann F Hubbs. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2 [J]. Am J Pathol, 2006, 168(6): 1960-1974.

[79] Jeong-Sang Lee, Young-Joon Surh. Nrf2 as a novel molecular target for chemoprevention [J]. Cancer Lett, 2005, 224(2): 171-184.

[80] Jong-Min Lee, Li Jiang, Delinda A Johnson, et al. Nrf2, a multi-organ protector? [J]. FASEB J, 2005, 19(9): 1061-1066.

[81] Jong-Min Lee, Jeffrey A Johnson. An important role of Nrf2-ARE pathway in the cellular defense mechanism [J]. J Biochem Mol Biol, 2004, 37(2): 139-143.

[82] Zhang Li-yuan, Zhu Zhen-hong, Liu Jian-hua, et al. Protective effect of N-acetylcysteine (NAC) on renal ischemia/reperfusion injury through Nrf2 signaling pathway [J]. J Recept Signal Transduct Res, 2014, 34(5):369-400.

[83] Blanco-Ayala T, Anderica-Romero A C, Pedraza-Chaverri J. New insights into antioxidant strategies against paraquat toxicity [J]. Free Radic Res, 2014, 48(6): 623-640.

[84] Ben A Barres. The mystery and magic of glia: a perspective on their roles in health and disease [J]. Neuron, 2008, 60(3): 430-440.

Glial Cells Protect Neurons against Oxidative Stress in Huntington’s Disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

[1]	XIE bin, HUANG Zhi-yuan, LIN Duo-duo, YANG Fu-long, XIE Yi-bin.Effect of Acupuncture Combined with Medicine on Depressive Symptoms of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 5-8.
[2]	SUN Li-cong, ZHANG Dan-shen.Research Progress on Potential Treatment of Alzheimer’s Disease with Alkaloids[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 33-37.
[3]	WANG Si-yi, LI Xian-xiang, LIU Yi-zhou, DU Shuang, GE Chao, LIU Si-si.Current Situation and Prospect of Alzeimer’s Disease Treatment[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 38-42.
[4]	ZHAO Yu-wei, ZHEN Yan-jie, DAI Yue-ying, SHEN Li-xia.Study on the Neuroprotective Mechanism of Quercetin in Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 55-64.
[5]	HAI Ji-tao, LUO Huan-min.Progress on the Relationship between Pathogenic Microorganisms and Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 58-64.
[6]	ZHANG Hao-ting, SONG Gui-qin, CUI Ruo-tong, HAO Min, WANG Wen-dong.Mining Target Genes of Alzheimer’s Disease Associated with Biological Clock by Bioinformatics Analysis[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 1-7.
[7]	YANG Xu-hua, DU Shuang, SHEN Li-xia, HAO Jun-rong.Research Progress in Drug Treatment of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 47-53.
[8]	LIN Si-mei, ZHOU Hong, YANG Bao-xue.The Relationship between Hyperuricemia and Chronic Kidney Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(2): 55-64.
[9]	ZHEN Yan-jie, GUO Tong-lin, ZHAO Yu-wei, SHEN Li-xia.Study Progress on Phytoestrogen-Mediated Mitochondrial Pathway’s Neuroprotective Effects in Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 40-46.
[10]	YANG-Lin，AI-Jing.Research Progress of Brain-Derived Estrogen in Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2019, 9(5): 50-64.
[11]	ZHANG Shuai，AI Jing.Glutamate Dysfunction and Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2018, 8(6): 9-20.
[12]	王奇.Bushen-Yizhi Formula Inhibits the NLRP3/NFκB Mediated Neuroinflammation and Improves the Motor Dysfunction in a Mouse Model of Parkinson's Disease[J]. Acta Neuropharmacologica, 2018, 8(5): 71-72.
[13]	CUI Su-ying, SONG Jin-zhi, CUI Xiang-yu, HU Xiao, DING Hui, YE Hui, ZHANG Yong-he.Intracerebroventricular Streptozocin-induced Alzheimer’s Disease-like Sleep Disorders: Role of the GABAergic System in the Parabrachial Complex[J]. Acta Neuropharmacologica, 2018, 8(5): 96-97.
[14]	YU Li-li1，2，XU Li1，WANG Yi-nuo1，XUE Lu-ning1，Gou Ji-wei1，LI Hong-bo1，HOU Xue-qin1，ZHANG Han-ting1.Effects of Osthole on Learning and Memory and the Estrogen Pathway in Ovariectomized Rats[J]. Acta Neuropharmacologica, 2018, 8(4): 7-8.
[15]	SHEN li-xia1，LIU Liang-liang1，ZHANG Ming1，LIU Yang1，ZHANG Dan-shen 2*.Research of Quercetin’s Estrogen-Like Action on Central Nervous System and Its Mechanisms[J]. Acta Neuropharmacologica, 2018, 8(4): 23-25.